Arrowhead Pharmaceuticals (ARWR) Income towards Parent Company (2010 - 2026)

Arrowhead Pharmaceuticals' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$137.6 million for Q1 2026.

• Quarterly Income towards Parent Company fell 137.4% year-over-year to -$137.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$271.9 million (down 75.8% YoY) and the FY2025 annual result came in at $30.1 million, up 104.94% from the prior year.
• Income towards Parent Company was -$137.6 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $28.2 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $367.9 million in Q1 2025 and bottomed at -$178.7 million in Q2 2025.
• A 5-year average of -$59.5 million and a median of -$104.1 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company tumbled 366.37% — and 2025, when it jumped 389.67%.
• Arrowhead Pharmaceuticals' Income towards Parent Company stood at -$41.8 million in 2022, then slumped by 223.91% to -$135.4 million in 2023, then dropped by 29.43% to -$175.2 million in 2024, then soared by 116.12% to $28.2 million in 2025, then plunged by 587.12% to -$137.6 million in 2026.
• Business Quant data shows ARWR's Income towards Parent Company at -$137.6 million in Q1 2026, $28.2 million in Q4 2025, and $16.1 million in Q3 2025.